NasdaqGM:ETONPharmaceuticals
What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?
Eton Pharmaceuticals (NasdaqGM: ETON) licensed U.S. rights to ASN-001, a potential first FDA-approved topical therapy for infantile hemangiomas, from Auson Pharmaceuticals.
The agreement centers on ASN-001, which targets an unmet need in pediatric dermatology where no FDA-approved topical treatments for infantile hemangiomas are currently available.
Eton plans to leverage its existing pediatric dermatology infrastructure, including HEMANGEOL, to support development and potential...